Congenital or hereditary myasthenia describes a heterogeneous group of disorders in which the immune system is not implicated. Treatment has previously depended on anticholinesterase medication. The effectiveness of 3,4-diaminopyridine (3,4-DAP), a preparation that enhances acetylcholine release from motor nerve terminals, has been evaluated using a series of standardised strength measures. Six...

Previous investigations have demonstrated that compounds capable of blocking presynaptic potassium channels can stimulate neurotransmitter release at both peripheral and central synapses. This study examined the in vitro effects of the "classical" potassium channel blockers 4-aminopyridine (4-AP) and tetraethylammonium (TEA) on the spontaneous basal release of [3H]5-hydroxytryptamine ([3H]5-HT)...

This work presents a comparative study of a series of halocarbonyl Mo(II) and W(II) complexes of the types [M(PNP)(CO)3X]X and [M(PNP)(CO)2X2] (M = Mo, W; X = I, Br), featuring PNP pincer ligands based on a 2,6-diaminopyridine scaffold. The complexes were prepared and fully characterized. The syntheses of these complexes were accomplished by treatment of [M(PNP)(CO)3] with stoichiometric amount...

In recent years, understanding of the pathogenesis and clinical presentation of distinct myasthenia subtypes has increased significantly. This article reviews the clinical manifestations of autoimmune myasthenia gravis (including myasthenia associated with anti-muscle-specific kinase antibodies), ocular myasthenia, and antibody negative myasthenia. The following treatments are examined: choline...

The reaction of iron(II) sulfate hepta-hydrate with the proton-transfer compound (pydaH)(hypydcH) (pyda = pyridine-2,6-diamine; hypydcH(2) = 4-hydroxy-pyridine-2,6-dicarboxylic acid) in an aqueous solution led to the formation of the title compound, (C(5)H(8)N(3))[Fe(C(7)H(3)NO(5))(2)]·2H(2)O. The anion is a six-coordinated complex with a distorted octa-hedral geometry around the Fe(III) atom. ...

ABSTRACT Several new monophosphorylated 2,6-diaminopyridine ligands bearing PiPr2 and PtBu2 units (PNNH2-iPr, PNNH2-tBu, PNNHMe-iPr, and PNNHEt-iPr) are prepared by treatment of the respective 2,6-diaminopyridines with the chlorophosphines PiPr2Cl and PtBu2Cl in the presence of a base. Treatment of anhydrous FeCl2 with 1 equiv of these afforded the tetracoordinated coordinatively unsaturated 14...